Tag Archive for: #ASN

Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

/in

The 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience Lund, Sweden, October 23, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that data […]

Read more

Hansa Biopharma announces Idefirix PAES late-breaking abstract selected for oral presentation in High-Impact Clinical Trials session at ASN Kidney Week

/in

Lund, Sweden, October 20, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the European Post-Authorization Efficacy and Safety (PAES) study of Idefirix® (imlifidase) has been selected by the Committee for an oral abstract presentation in the High-Impact Clinical Trials session at ASN Kidney Week in Denver, US. Read more…

Read more

R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026

/in

Poster will outline the design of R1’s ongoing global Phase 2b trial evaluating AP306 in patients with hyperphosphatemia AP306 is a potential first-in-class, oral, non-binder small molecule designed to inhibit all three intestinal phosphate transporters Phase 2b trial is enrolling across the US and China, with topline data expected in H1 2027 Redwood City, California […]

Read more

Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023

/in

CAMBRIDGE, UK, 2 November 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology’s Kidney Week in Philadelphia, from 2-5 November 2023. Mission Therapeutics is a world leader in discovering and developing novel […]

Read more
© Optimum Strategic Communications.